SeaStar Medical Holding Corp Stock Price, News & Analysis

SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage medical device company, has eliminated all long-term debt, strengthening its financial position. The company, which develops proprietary solutions to reduce hyperinflammation's impact on vital organs, reported over $9 million in convertible notes and long-term interest-bearing debt at the end of 2023. This debt retirement will be reflected in the balance sheet for the quarter ending September 30, 2024. CEO Eric Schlorff stated that SeaStar Medical is now in its strongest financial position since going public nearly two years ago, enhancing its ability to advance its business plan and deliver potentially life-saving solutions to critically ill patients.

SeaStar Medical (Nasdaq: ICU) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Initial commercial sales of QUELIMMUNE™ for pediatric AKI and sepsis patients.
2. Enrollment of 42 subjects at 9 sites in the NEUTRALIZE-AKI pivotal trial for adults.
3. CMS granted Category B coverage for certain trial expenses.
4. Completed a $10 million financing and retired nearly all outstanding debt.
5. Q2 2024 net loss of $3.2 million, or $1.03 per share.
6. Cash balance of approximately $6.9 million as of July 31, 2024.

The company expects U.S. regulatory approval for the SCD in adults with AKI in H1 2026, with commercial launch in H2 2026.

SeaStar Medical Holding (Nasdaq: ICU) has announced the first commercial treatment of a pediatric patient with its FDA-approved QUELIMMUNE™ therapeutic device. This milestone meets the FDA's August 20, 2024 deadline for initiating patient treatments. QUELIMMUNE is designed to treat acute kidney injury (AKI) in pediatric patients weighing 10 kg or more with sepsis or septic conditions requiring kidney replacement therapy (KRT).

Clinical trials have shown promising results, with a 77% survival rate and no dialysis dependency at 60 days for treated children. This is significant given that approximately 4,000 children with AKI require continuous KRT annually in the U.S., with a mortality rate of about 50%. The company aims to improve outcomes and reduce long-term complications for these severely ill children.

SeaStar Medical Holding (Nasdaq: ICU) has received a Category B Coverage Letter from CMS for its NEUTRALIZE-AKI pivotal trial, evaluating the Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). This coverage is expected to accelerate medical site activations and cover a portion of the trial costs. The trial aims to enroll up to 200 adult patients with AKI at up to 30 clinical sites, with 38 patients already enrolled across 10 active centers.

CEO Eric Schlorff anticipates that CMS reimbursement will provide substantial overall cost savings and accelerate patient enrollment. The company plans to conduct an interim analysis after reaching the 90-day primary endpoint in 100 enrolled subjects. SeaStar Medical views the adult AKI market as a multibillion-dollar opportunity, given its population is 50 times larger than pediatric AKI.

SeaStar Medical (Nasdaq: ICU) has announced the initial commercial sale of its QUELIMMUNE™-Pediatric to U.S. distributor Nuwellis. QUELIMMUNE, a patented cell-directed extracorporeal therapy, targets highly activated neutrophils and monocytes responsible for hyperactive immune responses in pediatric acute kidney injury (AKI) patients. The device is FDA-approved under a Humanitarian Device Exemption to treat pediatric AKI in patients weighing 10 kilograms or more. Initial studies show QUELIMMUNE has a probable benefit in reducing mortality and dialysis dependency. SeaStar Medical anticipates a significant commercial rollout by Q4 2024, with prestigious pediatric hospitals expected to meet HDE requirements this quarter. The company is also enrolling patients in the NEUTRALIZE-AKI trial for adults, presenting a multibillion-dollar market opportunity.

SeaStar Medical (Nasdaq: ICU) announced the closing of its $10 million registered direct offering. The company issued 947,868 shares of common stock at $10.55 per share. Concurrently, unregistered warrants for an additional 947,868 shares were issued at the same price, exercisable immediately and expiring in five years. Gross proceeds totaled $10 million before fees and expenses. H.C. Wainwright & Co. acted as the exclusive placement agent. Funds will support general corporate purposes, including working capital and debt repayment. The stock offering was filed under an effective SEC registration statement, while the warrants remain unregistered under the Securities Act.

SeaStar Medical has announced a $10 million registered direct offering priced at-the-market under Nasdaq rules. The offering involves the sale of 947,868 shares of common stock at $10.55 each, along with unregistered warrants for the same number of shares, which are exercisable immediately and expire in five years.

H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close on July 11, 2024, subject to customary conditions. The net proceeds will be used for general corporate purposes, including working capital and capital expenditures.

The shares are offered under a previously effective shelf registration statement, while the warrants are issued in a private placement and are not registered under the Securities Act.

SeaStar Medical (Nasdaq: ICU) has finalized FDA labeling for QUELIMMUNE™, a device aimed at reducing hyperinflammation in pediatric patients with acute kidney injury (AKI) and sepsis or septic conditions requiring kidney replacement therapy (KRT). This approval under the Humanitarian Use Device (HUD) designation allows SeaStar to market QUELIMMUNE in the U.S. for children weighing 10 kilograms or more. Clinical results showed a 77% survival rate, with no dialysis dependency at 60 days and no device-related serious adverse events. The device is expected to be available for shipment this month, addressing a U.S. market of approximately 4,000 children annually.

SeaStar Medical announced that its Selective Cytopheretic Device (SCD) will be featured in two presentations at the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology conference. The event takes place from June 11-13, 2024, in Vicenza, Italy. The SCD is a patented, cell-directed, extracorporeal device aimed at reducing hyperinflammation's impact on vital organs. One presentation, 'A Novel Selective Cytopheretic Device,' will be delivered by Dr. Stuart Goldstein from Cincinnati Children's Hospital. Another presentation, 'Cell-directed Therapy: Promising Approach to Sepsis and Other Dysregulated Immunological States, Including Acute Kidney Injury,' will be given by Dr. H. David Humes from the University of Michigan. Dr. Kevin Chung, SeaStar Medical's Chief Medical Officer, emphasized the honor of being invited by Dr. Claudio Ronco, a renowned expert in nephrology.